New Alzheimer's test bringing earlier diagnosis, earlier treatment

Fox - Fox 9
44 followers
Jul 21, 2026
AI Generated·May contain errors
Talk about some promising new research in the fight against Alzheimer's, blood
tests that could hold a promise to reveal earlier diagnoses, make those
diagnoses more available, widespread for doctors, maybe even help patients seek
earlier treatment, giving a predictor potentially of who's at risk for
developing Alzheimer's. Research presented last week at the Alzheimer's
Association International Conference in London. So let's bring in our guest, Dr.
Ronald Peterson of the Mayo Clinic, a neurologist, the former director of the
Mayo Clinic Alzheimer's Research Center, leads the Mayo Clinic study in aging.
Doctor, thank you for taking time today. My pleasure, thanks for having me, Rob.
Yeah, this is a disease that is so impactful to so many, not only those who
are fighting it, but their family members. I mean, the widespread impacts
here can be very, very devastating, and the research involved in the diagnosis
and treatment certainly has just utmost importance. Tell us about this
particular research. Two different studies presented last week that
involve the use of blood tests. Exactly, I mean, formerly we'd have to do either a
PET scan to look for the two proteins that cause Alzheimer's disease, amyloid
and tau in the brain. We either do a PET scan or we could do a lumbar puncture,
spinal tap, to detect the proteins in the cerebrospinal fluid. Those are pretty
accurate, but PET scans are expensive, lumbar puncture is invasive. So a blood
test opens up the new avenues for us to making the diagnosis much more quickly,
much more reliably, and more widespread across people in all parts of the
country. So this was exciting. At the same time, we can't jump to conclusions
right away that a blood test will definitively diagnose Alzheimer's
disease. We're doing some work down here in Rochester at the Mayo Clinic on the
use of these blood tests in the general community, and generally getting very
positive results. Now these blood tests, as I understand it, they still are trying
to detect the same two proteins that would be otherwise detected in the in
traditional diagnosis methods, right? That's exactly right. So when we talk
about Alzheimer's disease, we talk about the clinical picture of how a person
might be more forgetful than he or she used to be, having some trouble with
daily function, and then we ask the question, what's causing that clinical
picture? And here's where Alzheimer's disease comes in as a very common, but
not the only, cause of cognitive impairment. But we need to detect the
presence of those two proteins to nail down the diagnosis of Alzheimer's
disease. All right, one of the studies presented last week looked at how, with
these blood tests, if primary doctors had access to these blood test results, the
accuracy and diagnosis significantly improved. And I think you were quoted in
an article I read saying that, you know, not every doctor has access to this PET
scan technology. So tell us how that particular study, access to these
blood test results for doctors, improving diagnosis. Sure, so I think
that's reality. I mean, I'm a clinician, I make this clinical diagnosis,
but I don't always know if the clinical picture is due to Alzheimer's disease.
That's where the blood tests come in. So in this study, they said, doctor, what's
the likelihood this is Alzheimer's disease? The doctor said, thumbs up, thumbs
down. Then they did the blood test and improved the diagnostic accuracy of the
clinician. So that's enhanced our ability to determine whether people
might be eligible for now these drugs that are available to treat Alzheimer's
disease. What are the concerns about the accuracy of this test? I saw one
statistic saying 90% accuracy, but that doesn't mean you don't get false
positives. I think you had mentioned that the PET scan may indicate it, but
the blood test doesn't, or vice versa. So what are the concerns about this right
You've raised some relevant issues, Rob, that sometimes the blood test can kind of
overhaul the disease. So a false positive means that you get a positive blood
test, but in fact you do not have the amyloid protein in the brain. We try to
keep that as limited as possible, but it is real. So in our Mayo Clinic study of
aging down here in Rochester, Olmstead County, we found inconsistencies in both
directions. Positive blood test, negative PET scan, positive PET scan, negative
blood test. Consequently, before we make the decision to treat somebody with
these disease modifying therapies, we will validate the blood test with a PET
scan or a lumbar puncture. That's our current state, but I think the field's
evolving toward the accuracy improving with these blood tests. How much earlier
than could diagnosis be possible? Oh, quite early, quite early. In fact, I
mean, we can, there are now situations where we can do a blood test in somebody
who's clinically normal, but if they have a positive blood test means they may
have the underlying predisposition to the biology of Alzheimer's disease. There
are two clinical trials, drug trials underway right now for people who are
clinically normal, but have positive blood tests to see if in fact we can
delay the onset or postpone the symptoms over time. And I think the readout from
these two trials will come out in the next year or two or three. That'll be a
big deal because now we're talking about people who are clinically normal, but we
may be able to intervene early and hopefully prevent the disease. Yeah, and I
believe that was the second study presented at the International
Conference last week and then published in JAMA about how this can maybe predict
the, you know, the disposition for this five, ten years out. Yes, in fact, also in
that same session, my colleague Dr. Cliff Jack and Dr. Alicia Algeciras here
from Mayo presented data on our risk prediction formula where we can now,
again, based on the Mayo Clinic study of aging, we can plug in your age, your sex,
whether you have a genetic predisposition with this apolipoprotein E,
and then plug in a biomarker like a blood test and give you a prediction as
to what is the likelihood that you will develop cognitive impairment in the next
two years, five, ten, or in your lifetime. And that's incredibly important because
now if drugs become available in that situation, cognitively normal, positive
blood tests, do I want to take this drug? Might have some convenience issues, might
have some risk factors, might have some expense. I need to know what my risk of
developing cognitive impairment without treatment would be compared to what it
would be with treatment. And that's what the data that we've produced now will
help the decision-making process. So what's the availability of these blood
tests, Dan? Are these still purely in clinical trial forms or are they available
beyond that? Well, it's a touchy issue. They are available and actually there
are some direct-to-consumer which we're not wild about right now. We think these
need to be used in a clinical setting. I think your doctor needs to really order
these given your clinical situation rather than a home test. But they are
clinically available. They are clinically available. So the research is just
showing basically backing up that they can be very effective. Absolutely. The
research now is validating what a positive blood test means. Okay, well
where does this go then in the next several years in terms of better
diagnoses? But also, I mean, does this help inform any of the research into
better treatments? I think these blood tests can be used in one of three forms.
One is predicting who might be amyloid positive, have the biologic features of
Alzheimer's disease now. Secondly, what about the diagnosis? Can we make the
biologic diagnosis of Alzheimer's disease with a blood test? And most
exciting, can we use these blood tests to follow therapies? Since there are drugs
now that are available that lower the amount of the amyloid protein in the
brain, might we be able to follow the effectiveness of those therapies by
following a blood test? Like we do with cholesterol. We have elevated cholesterol.
We take a medication to lower that and we measure our cholesterol later on.
We're going to be able to do that, I think, with these blood tests for
Alzheimer's disease. Is this something too where somebody needs to get more than
one blood test in this process for diagnoses? Well, one should be good
depending on the accuracy as we discussed earlier, but you'll need
serial ones to see if in fact it's going up or going down, especially with
treatment. Okay, and then finally before I let you go, you know, for those who are
again looking out here over the next set of years, how would you describe, you know,
how rapidly we're evolving in terms of developing new treatments? Is this
something that is kind of stubbornly slow or is this something that
promises maybe some more rapid advances? It certainly had been slow for many
years, decades actually, but in the last few years now we've had two drugs
approved by the Food and Drug Administration for the treatment of
Alzheimer's disease. Others are under investigation right now that may do a
little better job and then ultimately where we're headed down the road is
combination therapy. So maybe a drug that's going to lower the amount of
amyloid in the brain and another drug that'll lower the amount of tau in the
brain, the other protein in Alzheimer's disease. So I think we're headed in a
positive direction for really slowing down this disease and maybe even
preventing it. Well that's good news because for many, many years people
weren't getting good news on the progress of treatment for this. It's been
a very, very frustrating thing for, I know, for folks like you in this field. So
thanks for taking the time to explain this and let's hope that this continues
to yield some very promising diagnoses and treatments.
